Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-90
SponsorJodi Maranchie

About this trial

This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image. Images will be reviewed by two dedicated abdominal radiologists, who are blinded to the pathologic staging, for determination of tumor presence and depth of bladder wall penetration.

Eligibility criteria

Qualifiers

18 to 90 years of age

Able to understand and willing to sign a written informed consent document

A papillary tumor identified by cystoscopy that has been scheduled for TURBT OR histologically proven MIBC that is clinically localized and amenable to surgical resection with curative intent.

Performance status of ECOG 0 or 1

Disqualifiers

Severe hypersensitivity reaction to gadobutrol or ferumoxytol.

Severe claustrophobia that will prevent completion of the MRI study.

Any MRI-non-compatible implanted device, prosthetic or pacemaker.

Known or suspected metastatic disease.

Trial design

Treatments tested in this trial

  • Magnetic Resonance Imaging
  • Gadobutrol intravesical administration (4mM)
  • Ferumoxytol intravesical administration (5 mM)

Treatment groups

42 Participants
are divided into 1 treatment group

Sponsors and collaborators

Jodi Maranchie

Lead sponsor

University of Pittsburgh

Sponsor institution

National Cancer Institute (NCI)

Collaborator